100 -2 (40) 2022 — Chukhliaev P.V., Janibekov J.J. — APPROACHES TO ETIOTROPIC THERAPY OF COVID-19 IN OUTPATIENT PATIENTS

APPROACHES TO ETIOTROPIC THERAPY OF COVID-19 IN OUTPATIENT PATIENTS

Chukhliaev P.V. Gabrichevsky Research Institute for Epidemiology and Microbiology Russian Federal Supervision Service for Consumer Rights Protection and People’s Welfare, Moscow, Russia

Janibekov J.J. Republican Children’s Infectious Diseases Hospital of the Republic of Karakalpakstan, Nukus, Uzbekistan

Garbuzov A.A. Gabrichevsky Research Institute for Epidemiology and Microbiology Russian Federal Supervision Service for Consumer Rights Protection and People’s Welfare, Moscow, Russia

Khavkina D.A. Gabrichevsky Research Institute for Epidemiology and Microbiology Russian Federal Supervision Service for Consumer Rights Protection and People’s Welfare, Moscow, Russia

MirzajonovaD.B. Republican Specialized Scientific and Practical Medical Center for Epidemiology, Microbiology, Infectious and Parasitic Diseases, Tashkent, Uzbekistan

Ruzhentsova T.A. Gabrichevsky Research Institute for Epidemiology and Microbiology Russian Federal Supervision Service for Consumer Rights Protection and People’s Welfare, Moscow, Russia

Resume

The article presents the results of a post-registration observational study to evaluate the results of early initiation of antiviral therapy in patients with COVID-19 receiving treatment at home.

The aim is to evaluate the efficacy and safety of antiviral therapy for the treatment of outpatient patients with coronavirus infection caused by SARS-COV-2.

Materials and methods. The study included 200 outpatient patients with COVID-19. Patients were divided into 3 groups: those who received favipiravir, umifenovir and those who did not receive antiviral agents.

Results. The median and interquartile interval to virus elimination while taking favipiravir was 3,0 (3.0; 5.0) days, among those receiving umifenovir – 5,0 (3.0; 7.0) days, without antiviral therapy – 8.5 (7.0; 10.0) days. Normalization of body temperature occurred faster with favipiravir therapy.

Conclusions. Antiviral therapy is effective and safe in outpatient patients with COVID-19. Taking favipiravir promotes earlier elimination of viruses. As an alternative antiviral drug, umifenovir may be prescribed to outpatient patients in the absence of a risk of severe course.

Keywords: COVID-19, SARS-CoV-2, coronavirus infection, umifenovir, favipiravir, virus elimination.

First page

508

Last page

511

For citation: Chukhliaev P.V., Janibekov J.J., Garbuzov A.A., Khavkina D.A., MirzajonovaD.B., Ruzhentsova T.A.APPROACHES TO ETIOTROPIC THERAPY OF COVID-19 IN OUTPATIENT PATIENTS //New Day in Medicine 2(40)2022 508-511 https://clck.ru/eSSmZ

LIST OF REFERENCES:

1. Временные методические рекомендации Минздрава России «Профилактика, диагностика и лечение коронавирусной инфекции (COVID-19)», версия 15 (22.02.2022). Москва. 2022. 224 с.
2. Shomuradova A.S., Vagida M.S., Sheetikov S.A. et al. SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors. Immunity. 2020;53(6):1245–1257.
3. Volz E., Hill V., McCrone J.T. et al. Evaluating the effects of SARSCoV-2 Spike mutation D614G on transmissibility and pathogenicity. Cell. 2020;184(1):33275900. doi.org/10.1016/ j.cell.2020.11.020.
4. Хавкина Д.А., Руженцова Т.А., Чухляев П.В., Гарбузов А.А., Шушакова Е.К. Роль дезинтоксикационной и антиоксидантной терапии в лечении COVID-19: теория и практика. Эпидемиология и инфекционные болезни. //Актуальные вопросы. 2020;10(2): 62-69.
5. Руженцова Т.А., Чухляев П.В., Хавкина Д.А. и др. Необходимость и безопасность применения фавипиравира в лечении взрослых пациентов с нетяжелыми формами COVID. Эпидемиология и инфекционные болезни. //Актуальные вопросы. 2020;10(4):38-44.